99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
An open-label, single center study with 99mTc-ADAPT6 SPECT and biopsies of primary tumour and
metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is
to find out the correlation between the HER2 expression measured by 99mTc-ADAPT6 SPECT and
standard histopathology from relevant tumor and lymph node biopsies.
Phase:
Phase 2
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences